NIH to Launch Massive ACTIV-6 Phase 3 Clinical Study Investigating Repurposed Drugs & Ivermectin May be on the List
NIH will provide an initial investment of $155 million in funding for the trial. TrialSite picked up inside rumblings that ivermectin will be one of the economical drugs under investigation. While this study is late in the pandemic, nonetheless TrialSite celebrates Collins and team’s movement in this most important of areas. We don’t currently have approved medication to be self-administered by people suffering mild disease at home & reduce the chance of needing hospitalization.